Oral contraceptives exposure may reduce the risk of ovarian cancer: a meta-analysis based on cohort studies

Background: Ovarian cancer ranks fourth in terms of incidence among gynecological malignancies and third as a cause of cancer death in the gynecological field, with oral contraceptives (OCs) exhibiting a potential relationship to ovarian cancer chemoprevention. This meta-analysis aimed to investigate the association between exposure to OCs and the incidence of ovarian cancer. Methods: Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, PubMed, Web of Science, Embase, and the Cochrane Library were searched for cohort studies on OCs and ovarian cancer incidence, covering the period from the establishment of each database to May 2025. Hazard ratio (HR) and 95% confidence interval (95% CI) were applied to assess the association between OCs and ovarian cancer incidence, with subgroup analyses performed for duration of use, time since OCs discontinuation, and geographical region. Results: = 53.6%). However, no significant difference in incidence was noted between both groups for individuals with an OCs exposure duration of less than 5 years (HR: 0.98, 95% CI: 0.84-1.16; P = 0.857), and a lower incidence was exclusively observed in the OCs exposure group with use lasting more than 5 years (HR: 0.66, 95% CI: 0.58-0.76; P < 0.001). Subgroup analysis revealed that in both European (HR: 0.74, 95% CI: 0.61-0.91; P = 0.004) and American (HR: 0.83, 95% CI: 0.68-1.01) cohorts, the incidence of ovarian cancer in the exposed group was lower than that in the control group. However, the difference in the latter did not reach statistical significance (P = 0.064), while no difference in ovarian cancer incidence was observed between the two groups in the Asian cohort (HR: 0.93, 95% CI: 0.71-1.23; P = 0.628). Conclusion: This study demonstrated that OCs exposure can exert a preventive effect on ovarian cancer, but such prevention necessitates a duration of use of more than 5 years, and the effect is impacted by geographical factors. In the future, OCs may emerge as one of the potential measures for ovarian cancer prevention.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-04-01
DOI
https://doi.org/10.3389/fphar.2026.1732719
Primary Topic
Reproductive Health and Contraception
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Oral contraceptives exposure may reduce the risk of ovarian cancer: a meta-analysis based on cohort studies

Ting Jiang, Jie Chen, H. J. Yang, Shiyan Zhang et al.
Frontiers in Pharmacology
Reproductive Health and Contraception
article

Oral contraceptives exposure may reduce the risk of ovarian cancer: a meta-analysis based on cohort studies

Ting Jiang, Jie Chen, H. J. Yang, Shiyan Zhang, Qian Sun, Jiani Ji
article en

Abstract

Background: Ovarian cancer ranks fourth in terms of incidence among gynecological malignancies and third as a cause of cancer death in the gynecological field, with oral contraceptives (OCs) exhibiting a potential relationship to ovarian cancer chemoprevention. This meta-analysis aimed to investigate the association between exposure to OCs and the incidence of ovarian cancer. Methods: Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, PubMed, Web of Science, Embase, and the Cochrane Library were searched for cohort studies on OCs and ovarian cancer incidence, covering the period from the establishment of each database to May 2025. Hazard ratio (HR) and 95% confidence interval (95% CI) were applied to assess the association between OCs and ovarian cancer incidence, with subgroup analyses performed for duration of use, time since OCs discontinuation, and geographical region. Results: = 53.6%). However, no significant difference in incidence was noted between both groups for individuals with an OCs exposure duration of less than 5 years (HR: 0.98, 95% CI: 0.84-1.16; P = 0.857), and a lower incidence was exclusively observed in the OCs exposure group with use lasting more than 5 years (HR: 0.66, 95% CI: 0.58-0.76; P < 0.001). Subgroup analysis revealed that in both European (HR: 0.74, 95% CI: 0.61-0.91; P = 0.004) and American (HR: 0.83, 95% CI: 0.68-1.01) cohorts, the incidence of ovarian cancer in the exposed group was lower than that in the control group. However, the difference in the latter did not reach statistical significance (P = 0.064), while no difference in ovarian cancer incidence was observed between the two groups in the Asian cohort (HR: 0.93, 95% CI: 0.71-1.23; P = 0.628). Conclusion: This study demonstrated that OCs exposure can exert a preventive effect on ovarian cancer, but such prevention necessitates a duration of use of more than 5 years, and the effect is impacted by geographical factors. In the future, OCs may emerge as one of the potential measures for ovarian cancer prevention.

Frontiers in PharmacologyVol. 17
Zhejiang Chinese Medical University (CN), Integrated Chinese Medicine (China) (HK)
Good health and well-being
Openalex Percentile: Top 32%
Reproductive Health and Contraception
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.